, a biopharmaceutical firm focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck to build up and commercialize AV-299 , its anti-hepatocyte growth aspect antibody candidate. In June 2010, AVEO initiated a Phase 2 clinical trial analyzing AV-299 in combination with gefitinib versus gefitinib monotherapy in patients with non-little cell lung malignancy . With the Stage 2 trial initiation, AVEO received an $8.5 million milestone payment from Merck under the terms of the permit agreement. Top-line efficacy data from the AV-299 Phase 2 trial are expected in past due 2011. Related StoriesMorphoSys, Immatics partner to build up novel antibody-centered therapies against multiple proprietary tumor antigensNew research offers potential for early intervention to avoid neurodegenerative diseasesCMC Biologics, River Eyesight sign manufacturing contract for Teprotumumab to take care of Grave's Orbitopathy’AVEO is very very happy to regain worldwide legal rights for the development and commercialization of AV-299,’ stated Tuan Ha-Ngoc, president and ceo of AVEO Pharmaceuticals.It’s a big assumption that nothing at all will change in the current outbreak response, said Dr. Armand Sprecher, an infectious diseases specialist at Doctors Without Borders. Ebola outbreaks end when people prevent touching the sick usually, he said. The outbreak won’t end tomorrow but there are issues we can do to lessen the case count. Local wellness officials have launched promotions to teach people about the symptoms of Ebola and not to touch the sick or the dead.